Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
| ▸ | CASP6 | P55212 | 2/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.44 |
| ▸ | CASP9 | P55211 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871025 | 0.83 | TACR1 (0.51) | CTSLCTSBCTSSCTSK | |
| SCHEMBL14158029 | 0.82 | CTSK (0.58) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL4873339 | 0.80 | ATM (0.49) | CASP3CASP1CASP7CASP6CASP8 | |
| SCHEMBL4872662 | 0.80 | CTRB1 (0.54) | CTSLCTSKELANE | |
| SCHEMBL18839695 | 0.79 | POLB (0.49) | CA2 | |
| SCHEMBL8219127 | 0.77 | CTSL (0.59) | CASP3CASP1CASP7CASP6CASP8 | |
| SCHEMBL8219125 | 0.77 | CTSL (0.59) | CASP3CASP1CASP7CASP6CASP8 | |
| SCHEMBL1908598 | 0.77 | CTSK (0.62) | CASP3CASP1CASP7CASP6CASP8 | |
| SCHEMBL4861590 | 0.76 | ACE (0.43) | CTSLCTSBCTSSCTSK | |
| SCHEMBL13008088 | 0.76 | CTSL (0.58) | CASP3CASP1CASP7CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900207-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-31 | — | — | US | claimed |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-08-14 | — | — | US | claimed |
| EP-1254901-A1 | NITROGEN-CONTAINING 5-MEMBERED CYCLIC COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20050164954-A1 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-07-28 | — | — | US | disclosed |
| US-6900207-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-31 | — | — | US | disclosed |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-08-14 | — | — | US | disclosed |
| EP-1254901-A1 | NITROGEN-CONTAINING 5-MEMBERED CYCLIC COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164954-A1 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ACIN1, CASP7, CASP10 | CASP3 18/4885CASP1 20/4885CASP7 2/4885 |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ACIN1, CASP7, CASP10 | CASP3 17/4885CASP1 7/4885CASP7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.